Cann Reiterates “Buy” Rating for Epizyme (EPZM)

Epizyme (NASDAQ:EPZM)‘s stock had its “buy” rating reaffirmed by analysts at Cann in a research report issued on Tuesday. They presently have a $26.00 target price on the biopharmaceutical company’s stock. Cann’s target price would indicate a potential upside of 96.23% from the company’s current price.

The analysts wrote, “Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook.””

Several other equities research analysts also recently commented on EPZM. BidaskClub upgraded Epizyme from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 5th. Oppenheimer restated a “buy” rating and set a $26.00 price objective on shares of Epizyme in a report on Tuesday, September 19th. Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Monday, October 16th. Jefferies Group assumed coverage on Epizyme in a report on Wednesday, September 20th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Leerink Swann restated an “outperform” rating and set a $22.00 price objective (down previously from $28.00) on shares of Epizyme in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $22.67.

Epizyme (NASDAQ:EPZM) opened at $13.25 on Tuesday. Epizyme has a 12 month low of $9.30 and a 12 month high of $20.45.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. sell-side analysts forecast that Epizyme will post -2.23 EPS for the current fiscal year.

In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $16.81, for a total transaction of $252,150.00. Following the completion of the sale, the insider now owns 23,123 shares in the company, valued at $388,697.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David M. Mott purchased 200,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were bought at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The disclosure for this purchase can be found here. Corporate insiders own 25.20% of the company’s stock.

A number of institutional investors have recently made changes to their positions in EPZM. Point72 Asset Management L.P. bought a new stake in Epizyme during the third quarter worth $17,591,000. Palo Alto Investors LLC grew its holdings in Epizyme by 18.9% during the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock worth $86,044,000 after buying an additional 907,245 shares in the last quarter. State Street Corp grew its holdings in Epizyme by 59.6% during the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after buying an additional 658,727 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in Epizyme during the second quarter worth $9,726,000. Finally, Bain Capital Public Equity Management LLC bought a new stake in Epizyme during the second quarter worth $4,331,000. Institutional investors and hedge funds own 85.28% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://stocknewstimes.com/2017/12/14/cann-reiterates-buy-rating-for-epizyme-epzm.html.

Epizyme Company Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply